{
    "abstract": "Biologics have transformed management of inflammatory diseases. To optimize outcomes and reduce costs, dose adjustment informed by circulating drug levels has been proposed. We aimed to determine the real-world clinical utility of therapeutic drug monitoring in psoriasis. Within a multicenter (n = 60) prospective observational cohort, 544 psoriasis patients were included who were receiving adalimumab monotherapy and had at least one serum sample and Psoriasis Area and Severity Index (PASI) score available within the first year. We present models giving individualized probabilities of response for any given drug level: a minimally effective drug level of 3.2 \u03bcg/ml discriminates responders (PASI75 indicates 75% improvement in baseline PASI) from nonresponders, and gives an estimated PASI75 probability of 65% (95% confidence interval = 60\u201371). At 7 \u03bcg/ml, PASI75 probability is 81% (95% CI = 76\u201386); beyond 7 \u03bcg/ml, the drug level/response curve plateaus. Crucially, drug levels are predictive of response 6 months later, whether sampled early or at steady state. We confirm serum drug level to be the most important factor determining treatment response, highlighting the need to take drug levels into account when searching for biomarkers of response. This real-world study with pragmatic drug level sampling provides evidence to support the proactive measurement of adalimumab levels in psoriasis to direct treatment strategy, and is relevant to other inflammatory diseases.",
    "bib_entries": {
        "bib1": null,
        "bib10": {
            "authors": [
                {
                    "first": "S. K.",
                    "initial": "S.K.",
                    "last": "Mahil"
                },
                {
                    "first": "Z.",
                    "initial": "Z.",
                    "last": "Arkir"
                },
                {
                    "first": "G.",
                    "initial": "G.",
                    "last": "Richards"
                },
                {
                    "first": "C. M.",
                    "initial": "C.M.",
                    "last": "Lewis"
                },
                {
                    "first": "J. N.",
                    "initial": "J.N.",
                    "last": "Barker"
                },
                {
                    "first": "C. H.",
                    "initial": "C.H.",
                    "last": "Smith"
                }
            ],
            "doi": "10.1111/bjd.12341",
            "firstpage": "306",
            "issn": "00070963",
            "lastpage": "313",
            "pmid": "23550925",
            "pub_year": 2013,
            "title": "Predicting treatment response in psoriasis using serum levels of adalimumab and etanercept: A single-centre, cohort study",
            "volume": "169"
        },
        "bib11": {
            "authors": [
                {
                    "first": "Stef P.",
                    "initial": "S.P.",
                    "last": "Menting"
                },
                {
                    "first": "Emma",
                    "initial": "E.",
                    "last": "Coussens"
                },
                {
                    "first": "Mieke F.",
                    "initial": "M.F.",
                    "last": "Pouw"
                },
                {
                    "first": "Juul M.P.A.",
                    "initial": "J.M.P.A.",
                    "last": "Van Den Reek"
                },
                {
                    "first": "Linda",
                    "initial": "L.",
                    "last": "Temmerman"
                },
                {
                    "first": "Hugo",
                    "initial": "H.",
                    "last": "Boonen"
                },
                {
                    "first": "Elke M.G.J.",
                    "initial": "E.M.G.J.",
                    "last": "De Jong"
                },
                {
                    "first": "Phyllis I.",
                    "initial": "P.I.",
                    "last": "Spuls"
                },
                {
                    "first": "Jo",
                    "initial": "J.",
                    "last": "Lambert"
                }
            ],
            "doi": "10.1001/jamadermatol.2014.5479",
            "firstpage": "616",
            "issn": "21686068",
            "lastpage": "622",
            "pmid": "25807311",
            "pub_year": 2015,
            "title": "Developing a therapeutic range of adalimumab serum concentrations in management of psoriasis a step toward personalized treatment",
            "volume": "151"
        },
        "bib12": {
            "authors": [
                {
                    "first": "N. M.",
                    "initial": "N.M.",
                    "last": "Mostafa"
                },
                {
                    "first": "A. M.",
                    "initial": "A.M.",
                    "last": "Nader"
                },
                {
                    "first": "P.",
                    "initial": "P.",
                    "last": "Noertersheuser"
                },
                {
                    "first": "M.",
                    "initial": "M.",
                    "last": "Okun"
                },
                {
                    "first": "W. M.",
                    "initial": "W.M.",
                    "last": "Awni"
                }
            ],
            "doi": "10.1111/jdv.13884",
            "firstpage": "490",
            "issn": "09269959",
            "lastpage": "497",
            "pmid": "27545848",
            "pub_year": 2017,
            "title": "Impact of immunogenicity on pharmacokinetics, efficacy and safety of adalimumab in adult patients with moderate to severe chronic plaque psoriasis",
            "volume": "31"
        },
        "bib13": {
            "authors": [
                {
                    "first": "Shinichi",
                    "initial": "S.",
                    "last": "Nakagawa"
                },
                {
                    "first": "Holger",
                    "initial": "H.",
                    "last": "Schielzeth"
                }
            ],
            "doi": "10.1111/j.2041-210x.2012.00261.x",
            "firstpage": "133",
            "issn": "2041210X",
            "lastpage": "142",
            "pub_year": 2013,
            "title": "A general and simple method for obtaining R2 from generalized linear mixed-effects models",
            "volume": "4"
        },
        "bib14": null,
        "bib15": {
            "authors": [
                {
                    "first": "Mieke F.",
                    "initial": "M.F.",
                    "last": "Pouw"
                },
                {
                    "first": "Charlotte L.",
                    "initial": "C.L.",
                    "last": "Krieckaert"
                },
                {
                    "first": "Michael T.",
                    "initial": "M.T.",
                    "last": "Nurmohamed"
                },
                {
                    "first": "Desiree",
                    "initial": "D.",
                    "last": "Van Der Kleij"
                },
                {
                    "first": "Lucien",
                    "initial": "L.",
                    "last": "Aarden"
                },
                {
                    "first": "Theo",
                    "initial": "T.",
                    "last": "Rispens"
                },
                {
                    "first": "Gertjan",
                    "initial": "G.",
                    "last": "Wolbink"
                }
            ],
            "doi": "10.1136/annrheumdis-2013-204172",
            "firstpage": "513",
            "issn": "00034967",
            "lastpage": "518",
            "pmid": "24326008",
            "pub_year": 2015,
            "title": "Key findings towards optimising adalimumab treatment: The concentration-effect curve",
            "volume": "74"
        },
        "bib16": {
            "authors": [
                {
                    "first": "Xavier",
                    "initial": "X.",
                    "last": "Roblin"
                },
                {
                    "first": "Hubert",
                    "initial": "H.",
                    "last": "Marotte"
                },
                {
                    "first": "Melanie",
                    "initial": "M.",
                    "last": "Rinaudo"
                },
                {
                    "first": "Emilie",
                    "initial": "E.",
                    "last": "Del Tedesco"
                },
                {
                    "first": "Amelie",
                    "initial": "A.",
                    "last": "Moreau"
                },
                {
                    "first": "Jean Marc",
                    "initial": "J.M.",
                    "last": "Phelip"
                },
                {
                    "first": "Christian",
                    "initial": "C.",
                    "last": "Genin"
                },
                {
                    "first": "Laurent",
                    "initial": "L.",
                    "last": "Peyrin-Biroulet"
                },
                {
                    "first": "Stephane",
                    "initial": "S.",
                    "last": "Paul"
                }
            ],
            "doi": "10.1016/j.cgh.2013.07.010",
            "firstpage": "80",
            "issn": "15423565",
            "lastpage": "e2",
            "pmid": "23891927",
            "pub_year": 2014,
            "title": "Association between pharmacokinetics of adalimumab and mucosal healing in patients with inflammatory bowel diseases",
            "volume": "12"
        },
        "bib17": {
            "authors": [
                {
                    "first": "Solveig K.",
                    "initial": "S.K.",
                    "last": "Sieberts"
                },
                {
                    "first": "Fan",
                    "initial": "F.",
                    "last": "Zhu"
                },
                {
                    "first": "Javier",
                    "initial": "J.",
                    "last": "Garc\u00eda-Garc\u00eda"
                },
                {
                    "first": "Eli",
                    "initial": "E.",
                    "last": "Stahl"
                },
                {
                    "first": "Abhishek",
                    "initial": "A.",
                    "last": "Pratap"
                },
                {
                    "first": "Gaurav",
                    "initial": "G.",
                    "last": "Pandey"
                },
                {
                    "first": "Dimitrios",
                    "initial": "D.",
                    "last": "Pappas"
                },
                {
                    "first": "Daniel",
                    "initial": "D.",
                    "last": "Aguilar"
                },
                {
                    "first": "Bernat",
                    "initial": "B.",
                    "last": "Anton"
                },
                {
                    "first": "Jaume",
                    "initial": "J.",
                    "last": "Bonet"
                },
                {
                    "first": "Ridvan",
                    "initial": "R.",
                    "last": "Eksi"
                },
                {
                    "first": "Oriol",
                    "initial": "O.",
                    "last": "Forn\u00e9s"
                },
                {
                    "first": "Emre",
                    "initial": "E.",
                    "last": "Guney"
                },
                {
                    "first": "Hongdong",
                    "initial": "H.",
                    "last": "Li"
                },
                {
                    "first": "Manuel Alejandro",
                    "initial": "M.A.",
                    "last": "Mar\u00edn"
                },
                {
                    "first": "Bharat",
                    "initial": "B.",
                    "last": "Panwar"
                },
                {
                    "first": "Joan",
                    "initial": "J.",
                    "last": "Planas-Iglesias"
                },
                {
                    "first": "Daniel",
                    "initial": "D.",
                    "last": "Poglayen"
                },
                {
                    "first": "Jing",
                    "initial": "J.",
                    "last": "Cui"
                },
                {
                    "first": "Andre O.",
                    "initial": "A.O.",
                    "last": "Falcao"
                },
                {
                    "first": "Christine",
                    "initial": "C.",
                    "last": "Suver"
                },
                {
                    "first": "Bruce",
                    "initial": "B.",
                    "last": "Hoff"
                },
                {
                    "first": "Venkat S.K.",
                    "initial": "V.S.K.",
                    "last": "Balagurusamy"
                },
                {
                    "first": "Donna",
                    "initial": "D.",
                    "last": "Dillenberger"
                },
                {
                    "first": "Elias Chaibub",
                    "initial": "E.C.",
                    "last": "Neto"
                },
                {
                    "first": "Thea",
                    "initial": "T.",
                    "last": "Norman"
                },
                {
                    "first": "Tero",
                    "initial": "T.",
                    "last": "Aittokallio"
                },
                {
                    "first": "Muhammad",
                    "initial": "M.",
                    "last": "Ammad-Ud-Din"
                },
                {
                    "first": "Chloe Agathe",
                    "initial": "C.A.",
                    "last": "Azencott"
                },
                {
                    "first": "V\u00edctor",
                    "initial": "V.",
                    "last": "Bell\u00f3n"
                },
                {
                    "first": "Valentina",
                    "initial": "V.",
                    "last": "Boeva"
                },
                {
                    "first": "Kerstin",
                    "initial": "K.",
                    "last": "Bunte"
                },
                {
                    "first": "Himanshu",
                    "initial": "H.",
                    "last": "Chheda"
                },
                {
                    "first": "Lu",
                    "initial": "L.",
                    "last": "Cheng"
                },
                {
                    "first": "Jukka",
                    "initial": "J.",
                    "last": "Corander"
                },
                {
                    "first": "Michel",
                    "initial": "M.",
                    "last": "Dumontier"
                },
                {
                    "first": "Anna",
                    "initial": "A.",
                    "last": "Goldenberg"
                },
                {
                    "first": "Peddinti",
                    "initial": "P.",
                    "last": "Gopalacharyulu"
                },
                {
                    "first": "Mohsen",
                    "initial": "M.",
                    "last": "Hajiloo"
                },
                {
                    "first": "Daniel",
                    "initial": "D.",
                    "last": "Hidru"
                },
                {
                    "first": "Alok",
                    "initial": "A.",
                    "last": "Jaiswal"
                },
                {
                    "first": "Samuel",
                    "initial": "S.",
                    "last": "Kaski"
                },
                {
                    "first": "Beyrem",
                    "initial": "B.",
                    "last": "Khalfaoui"
                },
                {
                    "first": "Suleiman Ali",
                    "initial": "S.A.",
                    "last": "Khan"
                },
                {
                    "first": "Eric R.",
                    "initial": "E.R.",
                    "last": "Kramer"
                },
                {
                    "first": "Pekka",
                    "initial": "P.",
                    "last": "Marttinen"
                },
                {
                    "first": "Aziz M.",
                    "initial": "A.M.",
                    "last": "Mezlini"
                },
                {
                    "first": "Bhuvan",
                    "initial": "B.",
                    "last": "Molparia"
                },
                {
                    "first": "Matti",
                    "initial": "M.",
                    "last": "Pirinen"
                },
                {
                    "first": "Janna",
                    "initial": "J.",
                    "last": "Saarela"
                },
                {
                    "first": "Matthias",
                    "initial": "M.",
                    "last": "Samwald"
                },
                {
                    "first": "V\u00e9ronique",
                    "initial": "V.",
                    "last": "Stoven"
                },
                {
                    "first": "Hao",
                    "initial": "H.",
                    "last": "Tang"
                },
                {
                    "first": "Jing",
                    "initial": "J.",
                    "last": "Tang"
                },
                {
                    "first": "Ali",
                    "initial": "A.",
                    "last": "Torkamani"
                },
                {
                    "first": "Jean Phillipe",
                    "initial": "J.P.",
                    "last": "Vert"
                },
                {
                    "first": "Bo",
                    "initial": "B.",
                    "last": "Wang"
                },
                {
                    "first": "Tao",
                    "initial": "T.",
                    "last": "Wang"
                },
                {
                    "first": "Krister",
                    "initial": "K.",
                    "last": "Wennerberg"
                },
                {
                    "first": "Nathan E.",
                    "initial": "N.E.",
                    "last": "Wineinger"
                },
                {
                    "first": "Guanghua",
                    "initial": "G.",
                    "last": "Xiao"
                },
                {
                    "first": "Yang",
                    "initial": "Y.",
                    "last": "Xie"
                },
                {
                    "first": "Rae",
                    "initial": "R.",
                    "last": "Yeung"
                },
                {
                    "first": "Xiaowei",
                    "initial": "X.",
                    "last": "Zhan"
                },
                {
                    "first": "Cheng",
                    "initial": "C.",
                    "last": "Zhao"
                },
                {
                    "first": "Jeff",
                    "initial": "J.",
                    "last": "Greenberg"
                },
                {
                    "first": "Joel",
                    "initial": "J.",
                    "last": "Kremer"
                },
                {
                    "first": "Kaleb",
                    "initial": "K.",
                    "last": "Michaud"
                },
                {
                    "first": "Anne",
                    "initial": "A.",
                    "last": "Barton"
                },
                {
                    "first": "Marieke",
                    "initial": "M.",
                    "last": "Coenen"
                },
                {
                    "first": "Xavier",
                    "initial": "X.",
                    "last": "Mariette"
                },
                {
                    "first": "Corinne",
                    "initial": "C.",
                    "last": "Miceli"
                },
                {
                    "first": "Nancy",
                    "initial": "N.",
                    "last": "Shadick"
                },
                {
                    "first": "Michael",
                    "initial": "M.",
                    "last": "Weinblatt"
                },
                {
                    "first": "Niek",
                    "initial": "N.",
                    "last": "De Vries"
                },
                {
                    "first": "Paul P.",
                    "initial": "P.P.",
                    "last": "Tak"
                },
                {
                    "first": "Danielle",
                    "initial": "D.",
                    "last": "Gerlag"
                },
                {
                    "first": "Tom W.J.",
                    "initial": "T.W.J.",
                    "last": "Huizinga"
                },
                {
                    "first": "Fina",
                    "initial": "F.",
                    "last": "Kurreeman"
                },
                {
                    "first": "Cornelia F.",
                    "initial": "C.F.",
                    "last": "Allaart"
                },
                {
                    "first": "S.",
                    "initial": "S.",
                    "last": "Louis Bridges"
                },
                {
                    "first": "Lindsey",
                    "initial": "L.",
                    "last": "Criswell"
                },
                {
                    "first": "Larry",
                    "initial": "L.",
                    "last": "Moreland"
                },
                {
                    "first": "Lars",
                    "initial": "L.",
                    "last": "Klareskog"
                },
                {
                    "first": "Saedis",
                    "initial": "S.",
                    "last": "Saevarsdottir"
                },
                {
                    "first": "Leonid",
                    "initial": "L.",
                    "last": "Padyukov"
                },
                {
                    "first": "Peter K.",
                    "initial": "P.K.",
                    "last": "Gregersen"
                },
                {
                    "first": "Stephen",
                    "initial": "S.",
                    "last": "Friend"
                },
                {
                    "first": "Robert",
                    "initial": "R.",
                    "last": "Plenge"
                },
                {
                    "first": "Gustavo",
                    "initial": "G.",
                    "last": "Stolovitzky"
                },
                {
                    "first": "Baldo",
                    "initial": "B.",
                    "last": "Oliva"
                },
                {
                    "first": "Yuanfang",
                    "initial": "Y.",
                    "last": "Guan"
                },
                {
                    "first": "Lara M.",
                    "initial": "L.M.",
                    "last": "Mangravite"
                },
                {
                    "first": null,
                    "initial": null,
                    "last": null
                }
            ],
            "doi": "10.1038/ncomms12460",
            "issn": "20411723",
            "pmid": "27549343",
            "pub_year": 2016,
            "title": "Crowdsourced assessment of common genetic contribution to predicting anti-TNF treatment response in rheumatoid arthritis",
            "volume": "7"
        },
        "bib18": {
            "authors": [
                {
                    "first": "Niels",
                    "initial": "N.",
                    "last": "Vande Casteele"
                },
                {
                    "first": "Marc",
                    "initial": "M.",
                    "last": "Ferrante"
                },
                {
                    "first": "Gert",
                    "initial": "G.",
                    "last": "Van Assche"
                },
                {
                    "first": "Vera",
                    "initial": "V.",
                    "last": "Ballet"
                },
                {
                    "first": "Griet",
                    "initial": "G.",
                    "last": "Compernolle"
                },
                {
                    "first": "Kristel",
                    "initial": "K.",
                    "last": "Van Steen"
                },
                {
                    "first": "Steven",
                    "initial": "S.",
                    "last": "Simoens"
                },
                {
                    "first": "Paul",
                    "initial": "P.",
                    "last": "Rutgeerts"
                },
                {
                    "first": "Ann",
                    "initial": "A.",
                    "last": "Gils"
                },
                {
                    "first": "S\u00e9verine",
                    "initial": "S.",
                    "last": "Vermeire"
                }
            ],
            "doi": "10.1053/j.gastro.2015.02.031",
            "firstpage": "1320",
            "issn": "00165085",
            "lastpage": "1329.e3",
            "pmid": "25724455",
            "pub_year": 2015,
            "title": "Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease",
            "volume": "148"
        },
        "bib19": {
            "authors": [
                {
                    "first": "R. B.",
                    "initial": "R.B.",
                    "last": "Warren"
                },
                {
                    "first": "A.",
                    "initial": "A.",
                    "last": "Marsden"
                },
                {
                    "first": "B.",
                    "initial": "B.",
                    "last": "Tomenson"
                },
                {
                    "first": "K. J.",
                    "initial": "K.J.",
                    "last": "Mason"
                },
                {
                    "first": "M. M.",
                    "initial": "M.M.",
                    "last": "Soliman"
                },
                {
                    "first": "A. D.",
                    "initial": "A.D.",
                    "last": "Burden"
                },
                {
                    "first": "N. J.",
                    "initial": "N.J.",
                    "last": "Reynolds"
                },
                {
                    "first": "D.",
                    "initial": "D.",
                    "last": "Stocken"
                },
                {
                    "first": "R.",
                    "initial": "R.",
                    "last": "Emsley"
                },
                {
                    "first": "C. E.M.",
                    "initial": "C.E.M.",
                    "last": "Griffiths"
                },
                {
                    "first": "C.",
                    "initial": "C.",
                    "last": "Smith"
                },
                {
                    "first": null,
                    "initial": null,
                    "last": null
                }
            ],
            "doi": "10.1111/bjd.16776",
            "firstpage": "1069",
            "issn": "00070963",
            "lastpage": "1076",
            "pmid": "30155885",
            "pub_year": 2019,
            "title": "Identifying demographic, social and clinical predictors of biologic therapy effectiveness in psoriasis: a multicentre longitudinal cohort study",
            "volume": "180"
        },
        "bib2": {
            "authors": [
                {
                    "first": "Filip",
                    "initial": "F.",
                    "last": "Baert"
                },
                {
                    "first": "Maja",
                    "initial": "M.",
                    "last": "Noman"
                },
                {
                    "first": "Severine",
                    "initial": "S.",
                    "last": "Vermeire"
                },
                {
                    "first": "Gert",
                    "initial": "G.",
                    "last": "Van Assche"
                },
                {
                    "first": "Geert",
                    "initial": "G.",
                    "last": "D'Haens"
                },
                {
                    "first": "An",
                    "initial": "A.",
                    "last": "Carbonez"
                },
                {
                    "first": "Paul",
                    "initial": "P.",
                    "last": "Rutgeerts"
                }
            ],
            "doi": "10.1056/NEJMoa020888",
            "firstpage": "601",
            "issn": "00284793",
            "lastpage": "608",
            "pmid": "12584368",
            "pub_year": 2003,
            "title": "Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease",
            "volume": "348"
        },
        "bib20": {
            "authors": [
                {
                    "first": "Richard B.",
                    "initial": "R.B.",
                    "last": "Warren"
                },
                {
                    "first": "Catherine H.",
                    "initial": "C.H.",
                    "last": "Smith"
                },
                {
                    "first": "Zenas Z.N.",
                    "initial": "Z.Z.N.",
                    "last": "Yiu"
                },
                {
                    "first": "Darren M.",
                    "initial": "D.M.",
                    "last": "Ashcroft"
                },
                {
                    "first": "Jonathan N.W.N.",
                    "initial": "J.N.W.N.",
                    "last": "Barker"
                },
                {
                    "first": "A. David",
                    "initial": "A.D.",
                    "last": "Burden"
                },
                {
                    "first": "Mark",
                    "initial": "M.",
                    "last": "Lunt"
                },
                {
                    "first": "Kathleen",
                    "initial": "K.",
                    "last": "McElhone"
                },
                {
                    "first": "Anthony D.",
                    "initial": "A.D.",
                    "last": "Ormerod"
                },
                {
                    "first": "Caroline M.",
                    "initial": "C.M.",
                    "last": "Owen"
                },
                {
                    "first": "Nick J.",
                    "initial": "N.J.",
                    "last": "Reynolds"
                },
                {
                    "first": "Christopher E.M.",
                    "initial": "C.E.M.",
                    "last": "Griffiths"
                }
            ],
            "doi": "10.1038/jid.2015.208",
            "firstpage": "2632",
            "issn": "0022202X",
            "lastpage": "2640",
            "pmid": "26053050",
            "pub_year": 2015,
            "title": "Differential Drug Survival of Biologic Therapies for the Treatment of Psoriasis: A Prospective Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR)",
            "volume": "135"
        },
        "bib21": {
            "authors": [
                {
                    "first": "Henit",
                    "initial": "H.",
                    "last": "Yanai"
                },
                {
                    "first": "Stephen B.",
                    "initial": "S.B.",
                    "last": "Hanauer"
                }
            ],
            "doi": "10.1038/ajg.2011.103",
            "firstpage": "685",
            "issn": "00029270",
            "lastpage": "698",
            "pmid": "21427713",
            "pub_year": 2011,
            "title": "Assessing response and loss of response to biological therapies in IBD",
            "volume": "106"
        },
        "bib22": {
            "authors": [
                {
                    "first": "Andres J.",
                    "initial": "A.J.",
                    "last": "Yarur"
                },
                {
                    "first": "Anjali",
                    "initial": "A.",
                    "last": "Jain"
                },
                {
                    "first": "Scott I.",
                    "initial": "S.I.",
                    "last": "Hauenstein"
                },
                {
                    "first": "Maria A.",
                    "initial": "M.A.",
                    "last": "Quintero"
                },
                {
                    "first": "Jamie S.",
                    "initial": "J.S.",
                    "last": "Barkin"
                },
                {
                    "first": "Amar R.",
                    "initial": "A.R.",
                    "last": "Deshpande"
                },
                {
                    "first": "Daniel A.",
                    "initial": "D.A.",
                    "last": "Sussman"
                },
                {
                    "first": "Sharat",
                    "initial": "S.",
                    "last": "Singh"
                },
                {
                    "first": "Maria T.",
                    "initial": "M.T.",
                    "last": "Abreu"
                }
            ],
            "doi": "10.1097/MIB.0000000000000689",
            "firstpage": "409",
            "issn": "10780998",
            "lastpage": "415",
            "pmid": "26752470",
            "pub_year": 2016,
            "title": "Higher Adalimumab Levels Are Associated with Histologic and Endoscopic Remission in Patients with Crohn's Disease and Ulcerative Colitis",
            "volume": "22"
        },
        "bib3": {
            "authors": [
                {
                    "first": "F.",
                    "initial": "F.",
                    "last": "Baert"
                },
                {
                    "first": "N.",
                    "initial": "N.",
                    "last": "Vande Casteele"
                },
                {
                    "first": "S.",
                    "initial": "S.",
                    "last": "Tops"
                },
                {
                    "first": "M.",
                    "initial": "M.",
                    "last": "Noman"
                },
                {
                    "first": "G.",
                    "initial": "G.",
                    "last": "Van Assche"
                },
                {
                    "first": "P.",
                    "initial": "P.",
                    "last": "Rutgeerts"
                },
                {
                    "first": "A.",
                    "initial": "A.",
                    "last": "Gils"
                },
                {
                    "first": "S.",
                    "initial": "S.",
                    "last": "Vermeire"
                },
                {
                    "first": "M.",
                    "initial": "M.",
                    "last": "Ferrante"
                }
            ],
            "doi": "10.1111/apt.12968",
            "firstpage": "1324",
            "issn": "02692813",
            "lastpage": "1332",
            "pmid": "25277873",
            "pub_year": 2014,
            "title": "Prior response to infliximab and early serum drug concentrations predict effects of adalimumab in ulcerative colitis",
            "volume": "40"
        },
        "bib4": {
            "authors": [
                {
                    "first": "Der Yuan",
                    "initial": "D.Y.",
                    "last": "Chen"
                },
                {
                    "first": "Yi Ming",
                    "initial": "Y.M.",
                    "last": "Chen"
                },
                {
                    "first": "Wen Chan",
                    "initial": "W.C.",
                    "last": "Tsai"
                },
                {
                    "first": "Jui Cheng",
                    "initial": "J.C.",
                    "last": "Tseng"
                },
                {
                    "first": "Yi Hsing",
                    "initial": "Y.H.",
                    "last": "Chen"
                },
                {
                    "first": "Chia Wei",
                    "initial": "C.W.",
                    "last": "Hsieh"
                },
                {
                    "first": "Wei Ting",
                    "initial": "W.T.",
                    "last": "Hung"
                },
                {
                    "first": "Joung Liang",
                    "initial": "J.L.",
                    "last": "Lan"
                }
            ],
            "doi": "10.1136/annrheumdis-2013-203893",
            "issn": "00034967",
            "pmid": "24442879",
            "pub_year": 2015,
            "title": "Significant associations of antidrug antibody levels with serum drug trough levels and therapeutic response of adalimumab and etanercept treatment in rheumatoid arthritis",
            "volume": "74"
        },
        "bib5": {
            "authors": [
                {
                    "first": "Sandra",
                    "initial": "S.",
                    "last": "Garc\u00eas"
                },
                {
                    "first": "Jocelyne",
                    "initial": "J.",
                    "last": "Demengeot"
                },
                {
                    "first": "Elizabeth",
                    "initial": "E.",
                    "last": "Benito-Garcia"
                }
            ],
            "doi": "10.1136/annrheumdis-2012-202220",
            "firstpage": "1947",
            "issn": "00034967",
            "lastpage": "1955",
            "pmid": "23223420",
            "pub_year": 2013,
            "title": "The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: A systematic review of the literature with a meta-analysis",
            "volume": "72"
        },
        "bib6": {
            "authors": [
                {
                    "first": "I. Y.K.",
                    "initial": "I.Y.K.",
                    "last": "Iskandar"
                },
                {
                    "first": "D. M.",
                    "initial": "D.M.",
                    "last": "Ashcroft"
                },
                {
                    "first": "R. B.",
                    "initial": "R.B.",
                    "last": "Warren"
                },
                {
                    "first": "Z. Z.N.",
                    "initial": "Z.Z.N.",
                    "last": "Yiu"
                },
                {
                    "first": "K.",
                    "initial": "K.",
                    "last": "McElhone"
                },
                {
                    "first": "M.",
                    "initial": "M.",
                    "last": "Lunt"
                },
                {
                    "first": "J. N.W.N.",
                    "initial": "J.N.W.N.",
                    "last": "Barker"
                },
                {
                    "first": "A. D.",
                    "initial": "A.D.",
                    "last": "Burden"
                },
                {
                    "first": "A. D.",
                    "initial": "A.D.",
                    "last": "Ormerod"
                },
                {
                    "first": "N. J.",
                    "initial": "N.J.",
                    "last": "Reynolds"
                },
                {
                    "first": "C. H.",
                    "initial": "C.H.",
                    "last": "Smith"
                },
                {
                    "first": "C. E.M.",
                    "initial": "C.E.M.",
                    "last": "Griffiths"
                }
            ],
            "doi": "10.1111/bjd.13908",
            "firstpage": "510",
            "issn": "00070963",
            "lastpage": "518",
            "pmid": "25989336",
            "pub_year": 2015,
            "title": "Demographics and disease characteristics of patients with psoriasis enrolled in the British Association of Dermatologists Biologic Interventions Register",
            "volume": "173"
        },
        "bib7": {
            "authors": [
                {
                    "first": "Shigeto",
                    "initial": "S.",
                    "last": "Kobayashi"
                },
                {
                    "first": "Masayoshi",
                    "initial": "M.",
                    "last": "Harigai"
                },
                {
                    "first": "Neelufar",
                    "initial": "N.",
                    "last": "Mozaffarian"
                },
                {
                    "first": "Aileen L.",
                    "initial": "A.L.",
                    "last": "Pangan"
                },
                {
                    "first": "Shringi",
                    "initial": "S.",
                    "last": "Sharma"
                },
                {
                    "first": "L. Steven",
                    "initial": "L.S.",
                    "last": "Brown"
                },
                {
                    "first": "Nobuyuki",
                    "initial": "N.",
                    "last": "Miyasaka"
                }
            ],
            "doi": "10.1007/s10165-011-0557-x",
            "firstpage": "589",
            "issn": "14397595",
            "lastpage": "597",
            "pmid": "22205117",
            "pub_year": 2012,
            "title": "A multicenter, open-label, efficacy, pharmacokinetic, and safety study of adalimumab in Japanese patients with ankylosing spondylitis",
            "volume": "22"
        },
        "bib8": {
            "authors": [
                {
                    "first": "C. L.M.",
                    "initial": "C.L.M.",
                    "last": "Krieckaert"
                },
                {
                    "first": "S. C.",
                    "initial": "S.C.",
                    "last": "Nair"
                },
                {
                    "first": "M. T.",
                    "initial": "M.T.",
                    "last": "Nurmohamed"
                },
                {
                    "first": "C. J.J.",
                    "initial": "C.J.J.",
                    "last": "Van Dongen"
                },
                {
                    "first": "W. F.",
                    "initial": "W.F.",
                    "last": "Lems"
                },
                {
                    "first": "F. P.J.G.",
                    "initial": "F.P.J.G.",
                    "last": "Lafeber"
                },
                {
                    "first": "J. W.J.",
                    "initial": "J.W.J.",
                    "last": "Bijlsma"
                },
                {
                    "first": "H.",
                    "initial": "H.",
                    "last": "Koffijberg"
                },
                {
                    "first": "G.",
                    "initial": "G.",
                    "last": "Wolbink"
                },
                {
                    "first": "P. M.J.",
                    "initial": "P.M.J.",
                    "last": "Welsing"
                }
            ],
            "doi": "10.1136/annrheumdis-2013-204101",
            "firstpage": "361",
            "issn": "00034967",
            "lastpage": "368",
            "pmid": "24265411",
            "pub_year": 2015,
            "title": "Personalised treatment using serum drug levels of adalimumab in patients with rheumatoid arthritis: An evaluation of costs and effects",
            "volume": "74"
        },
        "bib9": {
            "authors": [
                {
                    "first": "Lidian L.A.",
                    "initial": "L.L.A.",
                    "last": "Lecluse"
                },
                {
                    "first": "Rieke J.B.",
                    "initial": "R.J.B.",
                    "last": "Driessen"
                },
                {
                    "first": "Phyllis I.",
                    "initial": "P.I.",
                    "last": "Spuls"
                },
                {
                    "first": "Elke M.G.J.",
                    "initial": "E.M.G.J.",
                    "last": "De Jong"
                },
                {
                    "first": "Steven O.",
                    "initial": "S.O.",
                    "last": "Stapel"
                },
                {
                    "first": "Martijn B.A.",
                    "initial": "M.B.A.",
                    "last": "Van Doorn"
                },
                {
                    "first": "Jan D.",
                    "initial": "J.D.",
                    "last": "Bos"
                },
                {
                    "first": "Gert Jan",
                    "initial": "G.J.",
                    "last": "Wolbink"
                }
            ],
            "doi": "10.1001/archdermatol.2009.347",
            "firstpage": "127",
            "issn": "0003987X",
            "lastpage": "132",
            "pmid": "20157022",
            "pub_year": 2010,
            "title": "Extent and clinical consequences of antibody formation against adalimumab in patients with plaque psoriasis",
            "volume": "146"
        }
    },
    "body_text": [
        {
            "endOffset": 34323,
            "parents": [
                {
                    "id": "sec3",
                    "title": "Discussion"
                }
            ],
            "secId": "sec3.2",
            "sentence": "By comparison, our modeling approach may have an advantage in allowing for individualized prediction of response.",
            "startOffset": 34210,
            "title": "Context and clinical implications"
        },
        {
            "endOffset": 30786,
            "parents": [
                {
                    "id": "sec2",
                    "title": "Results"
                }
            ],
            "secId": "sec2.4",
            "sentence": "Bearing our therapeutic range in mind, 72 of 125 (57.60%) samples with a corresponding response less than PASI75 had a drug level below 3.2 \u03bcg/ml, and 69 of 171 (40.35%) samples with a corresponding PASI90 response had a drug level greater than or equal to 7 \u03bcg/ml.",
            "startOffset": 30521,
            "title": "Clinical utility of the therapeutic range"
        },
        {
            "endOffset": 40422,
            "parents": [
                {
                    "id": "sec5",
                    "title": "Materials and Methods"
                }
            ],
            "secId": "sec5.2",
            "sentence": "Detailed information is recorded, including demographics, comorbidities, treatments, and adverse effects.",
            "startOffset": 40317,
            "title": "Patients and setting"
        },
        {
            "endOffset": 45459,
            "parents": [],
            "secId": "sec7",
            "sentence": "NJR has received honoraria, travel support, and/or research grants (Newcastle University) from AbbVie, Almirall, Amgen, AstraZeneca, Bristol-Myers Squibb, Celgene, Genentech, Janssen, Leo-Pharma Research Foundation, Novartis, Pfizer, and Stiefel GSK.",
            "startOffset": 45209,
            "title": "Conflict of Interest"
        },
        {
            "endOffset": 42581,
            "parents": [
                {
                    "id": "sec5",
                    "title": "Materials and Methods"
                },
                {
                    "id": "sec5.5",
                    "title": "Statistical methods"
                }
            ],
            "refoffsets": {
                "bib11": {
                    "endOffset": 42421,
                    "startOffset": 42401
                }
            },
            "secId": "sec5.5.1",
            "sentence": "Empirical receiver operating characteristic curve analysis (Menting et al., 2015) was used to identify the lower limit of the therapeutic range\u2014specifically, the drug level at which responders are detected with a minimum sensitivity of 80%.",
            "startOffset": 42341,
            "title": "Identification of therapeutic range"
        },
        {
            "endOffset": 32084,
            "parents": [
                {
                    "id": "sec3",
                    "title": "Discussion"
                }
            ],
            "secId": "sec3.1",
            "sentence": "These key findings support the practical utility of measuring drug levels at routine clinical visits (irrespective of timing in relation to drug administration, and despite not being at trough levels) and provide drug level thresholds at which to consider changes in adalimumab treatment.",
            "startOffset": 31796,
            "title": "Key results"
        },
        {
            "endOffset": 42134,
            "parents": [
                {
                    "id": "sec5",
                    "title": "Materials and Methods"
                }
            ],
            "refoffsets": {
                "bib14": {
                    "endOffset": 42022,
                    "startOffset": 41967
                }
            },
            "secId": "sec5.5",
            "sentence": "Analyses for PASI75 and PASI90 responses were restricted to patients with baseline PASI greater than 10 as an accepted criterion for severe disease (National Institute for Health and Care Excellence, 2018) and to minimize confounding due to pre-biologic treatments\u2014of particular relevance in this real-world dataset.",
            "startOffset": 41818,
            "title": "Statistical methods"
        },
        {
            "endOffset": 21759,
            "parents": [],
            "secId": "sec1",
            "sentence": "Furthermore, biologics are generally used as monotherapy (whereas patients with IBD and RA are often co-prescribed immunosuppressants such as methotrexate, known to reduce the formation of ADAs).",
            "startOffset": 21564,
            "title": "Introduction"
        },
        {
            "endOffset": 30382,
            "parents": [
                {
                    "id": "sec2",
                    "title": "Results"
                }
            ],
            "secId": "sec2.4",
            "sentence": "Table 2 gives the standard estimates of clinical utility for our therapeutic range for PASI75 (3.2\u20137.0 \u03bcg/ml).",
            "startOffset": 30272,
            "title": "Clinical utility of the therapeutic range"
        },
        {
            "endOffset": 27060,
            "parents": [
                {
                    "id": "sec2",
                    "title": "Results"
                },
                {
                    "id": "sec2.2",
                    "title": "Defining the therapeutic range"
                }
            ],
            "secId": "sec2.2.3",
            "sentence": "We selected 7 \u03bcg/ml as the upper limit of the therapeutic range because this achieves our minimum stipulated 80% probability of response (81%, 95% CI = 76\u201386) (Figure 4), whereas the drug level at which the concentration effect curve appeared to plateau (4.6 \u03bcg/ml) has a lower probability of response (73%, 95% CI = 68\u201377).",
            "startOffset": 26736,
            "title": "Selecting an upper limit of the therapeutic range taking other covariates into account"
        },
        {
            "endOffset": 39576,
            "parents": [
                {
                    "id": "sec5",
                    "title": "Materials and Methods"
                }
            ],
            "secId": "sec5.1",
            "sentence": "Written informed consent was obtained from all subjects before enrolment.",
            "startOffset": 39503,
            "title": "Ethics approval"
        },
        {
            "endOffset": 21245,
            "parents": [],
            "refoffsets": {
                "bib10": {
                    "endOffset": 21243,
                    "startOffset": 21225
                }
            },
            "secId": "sec1",
            "sentence": "Furthermore, the utility of drug level as a predictor of subsequent response has not been investigated in psoriasis other than in a previous preliminary study by our group (Mahil et al., 2013).",
            "startOffset": 21052,
            "title": "Introduction"
        },
        {
            "endOffset": 30887,
            "parents": [
                {
                    "id": "sec2",
                    "title": "Results"
                }
            ],
            "secId": "sec2.4",
            "sentence": "This suggests that a significant proportion of the cohort would benefit from treatment modification.",
            "startOffset": 30787,
            "title": "Clinical utility of the therapeutic range"
        },
        {
            "endOffset": 33910,
            "parents": [
                {
                    "id": "sec3",
                    "title": "Discussion"
                }
            ],
            "refoffsets": {
                "bib18": {
                    "endOffset": 33908,
                    "startOffset": 33881
                }
            },
            "secId": "sec3.2",
            "sentence": "Such an approach has been tested in IBD, with the Trough Level Adapted Infliximab Treatment (TAXIT) trial showing similar remission rates in IBD patients on adjusted infliximab dosing based on drug level, but with fewer flares than the conventional approach (Vande Casteele et al., 2015).",
            "startOffset": 33622,
            "title": "Context and clinical implications"
        },
        {
            "endOffset": 34622,
            "parents": [
                {
                    "id": "sec3",
                    "title": "Discussion"
                }
            ],
            "secId": "sec3.2",
            "sentence": "Indeed, our data indicate that both the stringency of the outcome (for example PASI75 or PASI90) and the threshold set for the probability of response, need to be considered when defining the upper limit of the therapeutic range (and therefore the drug level chosen to implement dose minimization).",
            "startOffset": 34324,
            "title": "Context and clinical implications"
        },
        {
            "endOffset": 28157,
            "parents": [
                {
                    "id": "sec2",
                    "title": "Results"
                },
                {
                    "id": "sec2.3",
                    "title": "Using drug level to predict subsequent response"
                }
            ],
            "secId": "sec2.3.1",
            "sentence": "These same covariates were included in the final PASI90 model, and drug level and baseline PASI were included in the PASI\u22641.5 model (see Supplementary Table S4 online).",
            "startOffset": 27989,
            "title": "Early drug levels predict response at 6 months"
        },
        {
            "endOffset": 38844,
            "parents": [
                {
                    "id": "sec3",
                    "title": "Discussion"
                }
            ],
            "secId": "sec3.3",
            "sentence": "Indeed, the model fit as measured by pseudo R2 indicates that although drug level is important, this model could potentially be improved using covariates that have not been considered in this study.",
            "startOffset": 38646,
            "title": "Strengths and limitations"
        },
        {
            "endOffset": 31667,
            "parents": [
                {
                    "id": "sec3",
                    "title": "Discussion"
                }
            ],
            "secId": "sec3.1",
            "sentence": "As expected, there is a lower probability (51%) of achieving higher disease clearance (PASI90) at the same target drug level.",
            "startOffset": 31542,
            "title": "Key results"
        },
        {
            "endOffset": 34748,
            "parents": [
                {
                    "id": "sec3",
                    "title": "Discussion"
                }
            ],
            "secId": "sec3.2",
            "sentence": "This will help optimize cost effectiveness and minimize the proportion of patients subjected to inappropriate dose reduction.",
            "startOffset": 34623,
            "title": "Context and clinical implications"
        },
        {
            "endOffset": 43275,
            "parents": [
                {
                    "id": "sec5",
                    "title": "Materials and Methods"
                },
                {
                    "id": "sec5.5",
                    "title": "Statistical methods"
                }
            ],
            "secId": "sec5.5.1",
            "sentence": "Univariate mixed effects logistic regression models explored the relationship between treatment response and (i) drug level(ii) other confounding covariates including ADA, time from last dose, sex, age, and disease duration.",
            "startOffset": 43051,
            "title": "Identification of therapeutic range"
        },
        {
            "endOffset": 43418,
            "parents": [
                {
                    "id": "sec5",
                    "title": "Materials and Methods"
                },
                {
                    "id": "sec5.5",
                    "title": "Statistical methods"
                }
            ],
            "secId": "sec5.5.1",
            "sentence": "For continuous covariates, the best-fitting simple nonlinear transformation was chosen based on reduction in the Akaike Information Criterion.",
            "startOffset": 43276,
            "title": "Identification of therapeutic range"
        },
        {
            "endOffset": 32400,
            "parents": [
                {
                    "id": "sec3",
                    "title": "Discussion"
                }
            ],
            "refoffsets": {
                "bib11": {
                    "endOffset": 32293,
                    "startOffset": 32273
                }
            },
            "secId": "sec3.2",
            "sentence": "Our findings are consistent with the only other study conducted in psoriasis, which was dual-center and reported a therapeutic range of 3.51 to 7.00 \u03bcg/ml (Menting et al., 2015) but did not take into account clinical or other covariates such as ADAs, nor comment on clinical utility.",
            "startOffset": 32117,
            "title": "Context and clinical implications"
        },
        {
            "endOffset": 38645,
            "parents": [
                {
                    "id": "sec3",
                    "title": "Discussion"
                }
            ],
            "secId": "sec3.3",
            "sentence": "Finally, covariates are not always consistent across outcomes or datasets because of statistical artefacts when using different subsets of patients\u2014thus, our findings require replication.",
            "startOffset": 38458,
            "title": "Strengths and limitations"
        },
        {
            "endOffset": 35659,
            "parents": [
                {
                    "id": "sec3",
                    "title": "Discussion"
                }
            ],
            "refoffsets": {
                "bib14": {
                    "endOffset": 35657,
                    "startOffset": 35602
                }
            },
            "secId": "sec3.2",
            "sentence": "This is consistent with existing evidence that biologic-na\u00efve status may influence outcome (National Institute for Health and Care Excellence, 2018).",
            "startOffset": 35510,
            "title": "Context and clinical implications"
        },
        {
            "endOffset": 29202,
            "parents": [
                {
                    "id": "sec2",
                    "title": "Results"
                },
                {
                    "id": "sec2.3",
                    "title": "Using drug level to predict subsequent response"
                }
            ],
            "secId": "sec2.3.1",
            "sentence": "We found a similar relationship between drug levels and PASI75 response (see Supplementary Table S6 online).",
            "startOffset": 29094,
            "title": "Early drug levels predict response at 6 months"
        },
        {
            "endOffset": 25122,
            "parents": [
                {
                    "id": "sec2",
                    "title": "Results"
                },
                {
                    "id": "sec2.2",
                    "title": "Defining the therapeutic range"
                }
            ],
            "secId": "sec2.2.1",
            "sentence": "A lower limit of 3.2 \u03bcg/ml identified patients achieving PASI75 with our preset minimum sensitivity of 80% (red dot on Figure 3a; specificity = 58%, overall classification accuracy = 73%).",
            "startOffset": 24934,
            "title": "Drug level discriminates responders from nonresponders"
        },
        {
            "endOffset": 20553,
            "parents": [],
            "secId": "sec1",
            "sentence": "Indeed, a recent study using adalimumab clinical trial data in 1,212 psoriasis patients reported that responders at 16 weeks had higher adalimumab concentrations than nonresponders (6.3 vs. 2.2 \u03bcg/ml).",
            "startOffset": 20352,
            "title": "Introduction"
        },
        {
            "endOffset": 23532,
            "parents": [
                {
                    "id": "sec2",
                    "title": "Results"
                }
            ],
            "secId": "sec2.1",
            "sentence": "These 544 patients were included in the analysis (Table 1), and of these, 375 (69%) were biologic na\u00efve.",
            "startOffset": 23428,
            "title": "Description of the cohort and patient characteristics"
        },
        {
            "endOffset": 20722,
            "parents": [],
            "refoffsets": {
                "bib12": {
                    "endOffset": 20720,
                    "startOffset": 20700
                }
            },
            "secId": "sec1",
            "sentence": "Bodyweight was a significant covariate in the pharmacokinetic model, and the presence of ADAs resulted in lower adalimumab exposure and efficacy (Mostafa et al., 2017).",
            "startOffset": 20554,
            "title": "Introduction"
        },
        {
            "endOffset": 33487,
            "parents": [
                {
                    "id": "sec3",
                    "title": "Discussion"
                }
            ],
            "refoffsets": {
                "bib15": {
                    "endOffset": 33324,
                    "startOffset": 33307
                },
                "bib16": {
                    "endOffset": 33406,
                    "startOffset": 33367
                },
                "bib22": {
                    "endOffset": 33406,
                    "startOffset": 33367
                },
                "bib7": {
                    "endOffset": 33485,
                    "startOffset": 33463
                }
            },
            "secId": "sec3.2",
            "sentence": "Our results may be generalizable across other IMIDs, given comparable therapeutic ranges for adalimumab reported in RA (5\u20138 \u03bcg/ml) (Pouw et al., 2015) and IBD (5.0\u20135.9 \u03bcg/ml or 4.9\u20137.5 \u03bcg/ml [Roblin et al., 2014; Yarur et al., 2016]) and comparable mean levels in ankylosing spondylitis (Kobayashi et al., 2012).",
            "startOffset": 33175,
            "title": "Context and clinical implications"
        },
        {
            "endOffset": 26735,
            "parents": [
                {
                    "id": "sec2",
                    "title": "Results"
                },
                {
                    "id": "sec2.2",
                    "title": "Defining the therapeutic range"
                }
            ],
            "secId": "sec2.2.3",
            "sentence": "The results were consistent with the empirical analysis: for the primary outcome of PASI75, the best-fitting model included (transformed) drug level and ethnicity as covariates (Table 3, and see Supplementary Table S3 online), and the probability of PASI75 response plateaued with increasing drug level, supporting the concept of an upper-bounded therapeutic range (Figure 4).",
            "startOffset": 26359,
            "title": "Selecting an upper limit of the therapeutic range taking other covariates into account"
        },
        {
            "endOffset": 38982,
            "parents": [],
            "secId": "sec4",
            "sentence": "We provide evidence to support the proactive measurement of drug levels in the management of psoriasis with adalimumab therapy.",
            "startOffset": 38855,
            "title": "Conclusions"
        },
        {
            "endOffset": 41799,
            "parents": [
                {
                    "id": "sec5",
                    "title": "Materials and Methods"
                }
            ],
            "refoffsets": {
                "bib20": {
                    "endOffset": 41797,
                    "startOffset": 41755
                },
                "bib6": {
                    "endOffset": 41797,
                    "startOffset": 41755
                }
            },
            "secId": "sec5.4",
            "sentence": "Baseline PASI was defined as the most recent PASI recorded before the date of the first drug dose within the preceding 6 months (Iskandar et al., 2015; Warren et al., 2015).",
            "startOffset": 41626,
            "title": "Outcome measures"
        },
        {
            "endOffset": 22992,
            "parents": [
                {
                    "id": "sec2",
                    "title": "Results"
                }
            ],
            "secId": "sec2.1",
            "sentence": "At the time of the data cut in April 2017, 2028 patients were currently or previously receiving adalimumab monotherapy within the BSTOP cohort.",
            "startOffset": 22849,
            "title": "Description of the cohort and patient characteristics"
        },
        {
            "endOffset": 27836,
            "parents": [
                {
                    "id": "sec2",
                    "title": "Results"
                },
                {
                    "id": "sec2.3",
                    "title": "Using drug level to predict subsequent response"
                }
            ],
            "secId": "sec2.3.1",
            "sentence": "To determine whether drug levels indicate response status at later time points, multivariable logistic regression modeling was carried out using the early dataset (drug levels taken between 1 and 12 weeks, with PASI recorded at 6 months).",
            "startOffset": 27598,
            "title": "Early drug levels predict response at 6 months"
        },
        {
            "endOffset": 43540,
            "parents": [
                {
                    "id": "sec5",
                    "title": "Materials and Methods"
                },
                {
                    "id": "sec5.5",
                    "title": "Statistical methods"
                }
            ],
            "secId": "sec5.5.1",
            "sentence": "Covariates associated with response at significance level P < 0.1 were taken forward to the multivariable modeling stage.",
            "startOffset": 43419,
            "title": "Identification of therapeutic range"
        },
        {
            "endOffset": 37481,
            "parents": [
                {
                    "id": "sec3",
                    "title": "Discussion"
                }
            ],
            "secId": "sec3.3",
            "sentence": "In terms of potential limitations, the validity of the therapeutic range is limited to within 1 year of the start of treatment, because this was the selected cohort duration.",
            "startOffset": 37307,
            "title": "Strengths and limitations"
        },
        {
            "endOffset": 40316,
            "parents": [
                {
                    "id": "sec5",
                    "title": "Materials and Methods"
                }
            ],
            "secId": "sec5.2",
            "sentence": "Inclusion criteria include dermatologist\u2019s diagnosis of psoriasis; age older than 16 years; and started taking, or switched to, a conventional systemic therapy or a biological therapy within the previous 6 months.",
            "startOffset": 40103,
            "title": "Patients and setting"
        },
        {
            "endOffset": 37952,
            "parents": [
                {
                    "id": "sec3",
                    "title": "Discussion"
                }
            ],
            "secId": "sec3.3",
            "sentence": "On the other hand, the advent of adalimumab biosimilars at a fraction of the cost of the original drug, means that dose optimization strategies remain highly relevant.",
            "startOffset": 37785,
            "title": "Strengths and limitations"
        },
        {
            "endOffset": 39408,
            "parents": [
                {
                    "id": "sec5",
                    "title": "Materials and Methods"
                }
            ],
            "secId": "sec5.1",
            "sentence": "The study was conducted in the spirit of the 1996 International Conference on Harmonisation in Good Clinical Practice (ICH-GCP) 1996 and in accordance with the 2008 Declaration of Helsinki.",
            "startOffset": 39219,
            "title": "Ethics approval"
        },
        {
            "endOffset": 31190,
            "parents": [
                {
                    "id": "sec3",
                    "title": "Discussion"
                }
            ],
            "secId": "sec3.1",
            "sentence": "In the largest real-world, multicenter cohort across any IMID to date, we determined the therapeutic range for adalimumab in moderate to severe psoriasis and calculated probabilities of response for any given drug level for multiple outcomes (PASI75, PASI90, and absolute PASI\u22641.5).",
            "startOffset": 30908,
            "title": "Key results"
        },
        {
            "endOffset": 44453,
            "parents": [
                {
                    "id": "sec5",
                    "title": "Materials and Methods"
                },
                {
                    "id": "sec5.5",
                    "title": "Statistical methods"
                }
            ],
            "refoffsets": {
                "bib1": {
                    "endOffset": 44378,
                    "startOffset": 44361
                }
            },
            "secId": "sec5.5.2",
            "sentence": "To investigate whether drug level predicts subsequent outcome, two further datasets were derived: an early dataset comprising samples taken between 1 and 12 weeks with a corresponding PASI 6 months (122\u2013243 days) after start of treatment and a steady state dataset comprising samples taken at steady state (\u22659 weeks [Awni et al., 2003]) with a corresponding PASI 6 months (122\u2013243 days) after the sample date.",
            "startOffset": 44044,
            "title": "Using drug level to predict subsequent response"
        },
        {
            "endOffset": 23124,
            "parents": [
                {
                    "id": "sec2",
                    "title": "Results"
                }
            ],
            "secId": "sec2.1",
            "sentence": "Of these, 1,242 consented to give longitudinal serum samples; within this, serum samples were actually collected from 833 patients.",
            "startOffset": 22993,
            "title": "Description of the cohort and patient characteristics"
        },
        {
            "endOffset": 24029,
            "parents": [
                {
                    "id": "sec2",
                    "title": "Results"
                }
            ],
            "secId": "sec2.1",
            "sentence": "Drug levels were sampled according to standard clinical care (median time from last dose = 7 days, interquartile range = 6\u201310 days, range = 0\u201314 days, data available on n = 349 samples), giving a mean drug level of 5.83 \u03bcg/ml (standard deviation = 3.86, range = 0.01\u201322 \u03bcg/ml).",
            "startOffset": 23752,
            "title": "Description of the cohort and patient characteristics"
        },
        {
            "endOffset": 45208,
            "parents": [],
            "secId": "sec7",
            "sentence": "CEMG has received honoraria and/or research grant support (University of Manchester) from AbbVie, Almirall, Bristol Meyers Squibb, Celgene, GSK, Janssen, LEO Foundation, Lilly, Novartis, Pfizer, Sandoz, Sun Pharma, and UCB Pharma.",
            "startOffset": 44978,
            "title": "Conflict of Interest"
        },
        {
            "endOffset": 28737,
            "parents": [
                {
                    "id": "sec2",
                    "title": "Results"
                },
                {
                    "id": "sec2.3",
                    "title": "Using drug level to predict subsequent response"
                }
            ],
            "secId": "sec2.3.1",
            "sentence": "The upper limit of 7 \u03bcg/ml (defined in the therapeutic range dataset) (Figure 4) corresponds to a 78% (95% CI = 71\u201385) probability of 6-month response using early drug levels (Table 2, and see Supplementary Figure S2a).",
            "startOffset": 28518,
            "title": "Early drug levels predict response at 6 months"
        },
        {
            "endOffset": 35984,
            "parents": [
                {
                    "id": "sec3",
                    "title": "Discussion"
                }
            ],
            "refoffsets": {
                "bib19": {
                    "endOffset": 35982,
                    "startOffset": 35963
                }
            },
            "secId": "sec3.2",
            "sentence": "Across the BADBIR cohort as a whole, we found non-white ethnicity to be associated with a reduced likelihood of response to biologics up to 1 year (Warren et al., 2018).",
            "startOffset": 35815,
            "title": "Context and clinical implications"
        },
        {
            "endOffset": 45832,
            "parents": [],
            "secId": "sec7",
            "sentence": "RBW has received honoraria and/or research grants from AbbVie, Almirall, Amgen, Boehringer Ingelheim, Celgene, Janssen, Leo, Lilly, Novartis, Pfizer, Sanofi, Xenoport, and UCB.",
            "startOffset": 45656,
            "title": "Conflict of Interest"
        },
        {
            "endOffset": 40102,
            "parents": [
                {
                    "id": "sec5",
                    "title": "Materials and Methods"
                }
            ],
            "secId": "sec5.2",
            "sentence": "BADBIR has recruited more than 12,000 psoriasis patients since 2007 and is unique worldwide in terms of size and depth of phenotyping.",
            "startOffset": 39968,
            "title": "Patients and setting"
        },
        {
            "endOffset": 20351,
            "parents": [],
            "refoffsets": {
                "bib2": {
                    "endOffset": 20349,
                    "startOffset": 20290
                },
                "bib4": {
                    "endOffset": 20349,
                    "startOffset": 20290
                },
                "bib9": {
                    "endOffset": 20349,
                    "startOffset": 20290
                }
            },
            "secId": "sec1",
            "sentence": "Therapeutic drug monitoring using measurement of serum drug levels (a proxy for tissue levels) and/or ADAs thus holds potential to optimize management, and a strong correlation between TNF inhibitor serum trough levels, ADAs, and treatment response has been described in IBD, RA, and psoriasis (Baert et al., 2003; Chen et al., 2015; Lecluse et al., 2010).",
            "startOffset": 19995,
            "title": "Introduction"
        },
        {
            "endOffset": 26358,
            "parents": [
                {
                    "id": "sec2",
                    "title": "Results"
                },
                {
                    "id": "sec2.2",
                    "title": "Defining the therapeutic range"
                }
            ],
            "secId": "sec2.2.3",
            "sentence": "To take clinical and confounding covariates into account, multivariable mixed effects logistic regression modelling was carried out using the therapeutic range dataset.",
            "startOffset": 26190,
            "title": "Selecting an upper limit of the therapeutic range taking other covariates into account"
        },
        {
            "endOffset": 35323,
            "parents": [
                {
                    "id": "sec3",
                    "title": "Discussion"
                }
            ],
            "secId": "sec3.2",
            "sentence": "The finding that biologic-na\u00efve status and ethnicity may predict longer-term response requires further validation, because these covariates were not consistent across outcomes.",
            "startOffset": 35147,
            "title": "Context and clinical implications"
        },
        {
            "endOffset": 35147,
            "parents": [
                {
                    "id": "sec3",
                    "title": "Discussion"
                }
            ],
            "secId": "sec3.2",
            "sentence": "In turn, this may indicate that in patients for whom clinical response plateaus at a lower drug level, alternative non-TNF pathways possibly play a greater role in driving their psoriasis.",
            "startOffset": 34959,
            "title": "Context and clinical implications"
        },
        {
            "endOffset": 42730,
            "parents": [
                {
                    "id": "sec5",
                    "title": "Materials and Methods"
                },
                {
                    "id": "sec5.5",
                    "title": "Statistical methods"
                }
            ],
            "refoffsets": {
                "bib11": {
                    "endOffset": 42643,
                    "startOffset": 42623
                }
            },
            "secId": "sec5.5.1",
            "sentence": "A descriptive concentration effect curve (Menting et al., 2015) was generated to confirm that clinical response plateaus beyond a certain drug level.",
            "startOffset": 42581,
            "title": "Identification of therapeutic range"
        },
        {
            "endOffset": 23262,
            "parents": [
                {
                    "id": "sec2",
                    "title": "Results"
                }
            ],
            "secId": "sec2.1",
            "sentence": "Baseline characteristics were similar between those providing and not providing samples (Table 1, and see Supplementary Table S1 online).",
            "startOffset": 23125,
            "title": "Description of the cohort and patient characteristics"
        },
        {
            "endOffset": 29951,
            "parents": [
                {
                    "id": "sec2",
                    "title": "Results"
                },
                {
                    "id": "sec2.3",
                    "title": "Using drug level to predict subsequent response"
                }
            ],
            "secId": "sec2.3.2",
            "sentence": "Again, for the primary outcome of PASI75, (transformed) drug level was the single most important predictor of response (odds ratio [square root of drug level] = 2.78, 95% CI = 1.83\u20134.24, P < 0.001) (Table 3), with increasing probability of response with increasing drug level (see Supplementary Figure S3a).",
            "startOffset": 29644,
            "title": "Steady state drug levels predict response 6 months later"
        },
        {
            "endOffset": 43050,
            "parents": [
                {
                    "id": "sec5",
                    "title": "Materials and Methods"
                },
                {
                    "id": "sec5.5",
                    "title": "Statistical methods"
                }
            ],
            "secId": "sec5.5.1",
            "sentence": "A random intercept term was used to account for correlation between repeated samples on the same patient.",
            "startOffset": 42945,
            "title": "Identification of therapeutic range"
        },
        {
            "endOffset": 38253,
            "parents": [
                {
                    "id": "sec3",
                    "title": "Discussion"
                }
            ],
            "secId": "sec3.3",
            "sentence": "Another potential limitation is use of pragmatic serum sampling at routine clinic visits; to account for the timing of samples we included time from last dose as a covariate, and although this was not significant at the univariate level, we only had these data available on around a third of samples.",
            "startOffset": 37953,
            "title": "Strengths and limitations"
        },
        {
            "endOffset": 36626,
            "parents": [
                {
                    "id": "sec3",
                    "title": "Discussion"
                }
            ],
            "refoffsets": {
                "bib17": {
                    "endOffset": 36624,
                    "startOffset": 36603
                }
            },
            "secId": "sec3.2",
            "sentence": "Indeed, the need to incorporate a richer set of clinical information, such as seropositivity and disease duration, was recently highlighted in an innovative crowdsourced assessment of the common genetic contribution to predicting TNF antagonist treatment response in RA (Sieberts et al., 2016).",
            "startOffset": 36332,
            "title": "Context and clinical implications"
        },
        {
            "endOffset": 31541,
            "parents": [
                {
                    "id": "sec3",
                    "title": "Discussion"
                }
            ],
            "secId": "sec3.1",
            "sentence": "A minimal effective circulating drug level of 3.2 \u03bcg/ml distinguishes PASI75 responders from nonresponders, and a target drug level of 7 \u03bcg/ml provides an 80% probability of achieving a PASI75 response.",
            "startOffset": 31339,
            "title": "Key results"
        },
        {
            "endOffset": 39502,
            "parents": [
                {
                    "id": "sec5",
                    "title": "Materials and Methods"
                }
            ],
            "secId": "sec5.1",
            "sentence": "The study protocol was approved by The South East London REC 2 Ethics Committee (11/H0802/7).",
            "startOffset": 39409,
            "title": "Ethics approval"
        },
        {
            "endOffset": 45953,
            "parents": [],
            "secId": "sec7",
            "sentence": "ADB has received honoraria from AbbVie, Amgen, Boehringer Ingelheim, Celgene, Janssen, Leo, Lilly, Novartis, and Pfizer.",
            "startOffset": 45833,
            "title": "Conflict of Interest"
        },
        {
            "endOffset": 44749,
            "parents": [
                {
                    "id": "sec5",
                    "title": "Materials and Methods"
                },
                {
                    "id": "sec5.5",
                    "title": "Statistical methods"
                }
            ],
            "secId": "sec5.5.2",
            "sentence": "For the early dataset, a random effect was not included because of the small number of patients with multiple samples.",
            "startOffset": 44631,
            "title": "Using drug level to predict subsequent response"
        },
        {
            "endOffset": 19727,
            "parents": [],
            "refoffsets": {
                "bib21": {
                    "endOffset": 19725,
                    "startOffset": 19681
                },
                "bib5": {
                    "endOffset": 19725,
                    "startOffset": 19681
                }
            },
            "secId": "sec1",
            "sentence": "However, there are wide variations in response, with a significant number of patients not responding (primary treatment failure) or losing response over time (secondary treatment failure) (Garces et al., 2013; Yanai and Hanauer, 2011).",
            "startOffset": 19492,
            "title": "Introduction"
        },
        {
            "endOffset": 32947,
            "parents": [
                {
                    "id": "sec3",
                    "title": "Discussion"
                }
            ],
            "secId": "sec3.2",
            "sentence": "This may open up a powerful clinical opportunity to optimize therapy before drug levels have reached steady state, well ahead of clinical relapse.",
            "startOffset": 32801,
            "title": "Context and clinical implications"
        },
        {
            "endOffset": 46061,
            "parents": [],
            "secId": "sec7",
            "sentence": "TR has received honoraria for lectures from Pfizer, AbbVie, and Regeneron and a research grant from Genmab.",
            "startOffset": 45954,
            "title": "Conflict of Interest"
        },
        {
            "endOffset": 25901,
            "parents": [
                {
                    "id": "sec2",
                    "title": "Results"
                },
                {
                    "id": "sec2.2",
                    "title": "Defining the therapeutic range"
                }
            ],
            "refoffsets": {
                "bib11": {
                    "endOffset": 25628,
                    "startOffset": 25608
                }
            },
            "secId": "sec2.2.2",
            "sentence": "Using the therapeutic range dataset (drug levels with PASI recorded on the same day), a descriptive concentration effect curve (Menting et al., 2015) was next generated to confirm that clinical response increases with increasing drug level, then plateaus for groups with median drug level of 4.6 \u03bcg/ml or greater (red dot on Figure 3b), corresponding to a percent PASI change of 90.7% (IQR = 83.7\u201399.4, range = 16.2\u2013100).",
            "startOffset": 25480,
            "title": "Likelihood of response increases with increasing drug level and then plateaus"
        },
        {
            "endOffset": 30231,
            "parents": [
                {
                    "id": "sec2",
                    "title": "Results"
                },
                {
                    "id": "sec2.3",
                    "title": "Using drug level to predict subsequent response"
                }
            ],
            "secId": "sec2.3.2",
            "sentence": "This relationship between drug level and response was also seen using the PASI90 and PASI\u22641.5 outcomes (see Supplementary Table S4 and Supplementary Figure S3b and c); the covariates palm psoriasis and biologic-na\u00efve status were also significant for these outcomes, respectively.",
            "startOffset": 29952,
            "title": "Steady state drug levels predict response 6 months later"
        },
        {
            "endOffset": 33621,
            "parents": [
                {
                    "id": "sec3",
                    "title": "Discussion"
                }
            ],
            "secId": "sec3.2",
            "sentence": "A minimal effective drug level indicates the threshold below which treatment should be modified (dose escalation or treatment switch).",
            "startOffset": 33487,
            "title": "Context and clinical implications"
        },
        {
            "endOffset": 46125,
            "parents": [],
            "secId": "sec7",
            "sentence": "DS has received departmental research funding from AstraZeneca.",
            "startOffset": 46062,
            "title": "Conflict of Interest"
        },
        {
            "endOffset": 22368,
            "parents": [],
            "secId": "sec1",
            "sentence": "This work is particularly timely with the imminent release of adalimumab biosimilar products to market, because optimizing outcomes may deliver comparable efficacy to newer biologics, but at significantly lower cost.",
            "startOffset": 22152,
            "title": "Introduction"
        },
        {
            "endOffset": 27322,
            "parents": [
                {
                    "id": "sec2",
                    "title": "Results"
                },
                {
                    "id": "sec2.2",
                    "title": "Defining the therapeutic range"
                }
            ],
            "secId": "sec2.2.3",
            "sentence": "Additional covariates appear significant for PASI90 (baseline PASI, treatment duration, and biologic-na\u00efve status) and PASI\u22641.5 (sex and biologic-na\u00efve status).",
            "startOffset": 27162,
            "title": "Selecting an upper limit of the therapeutic range taking other covariates into account"
        },
        {
            "endOffset": 29093,
            "parents": [
                {
                    "id": "sec2",
                    "title": "Results"
                },
                {
                    "id": "sec2.3",
                    "title": "Using drug level to predict subsequent response"
                }
            ],
            "refoffsets": {
                "bib10": {
                    "endOffset": 29009,
                    "startOffset": 28991
                }
            },
            "secId": "sec2.3.1",
            "sentence": "We also performed a sensitivity analysis by fitting the model to very early samples (4 weeks \u00b1 1 week after treatment initiation), given our pilot data showing that higher adalimumab levels in responders versus nonresponders were detectable at 4 weeks (Mahil et al., 2013), and acknowledging the overlap between our early dataset and steady state dataset.",
            "startOffset": 28738,
            "title": "Early drug levels predict response at 6 months"
        },
        {
            "endOffset": 46365,
            "parents": [],
            "secId": "sec7",
            "sentence": "The PSORT consortium has a number of industry partners; see www.psort.org.uk.",
            "startOffset": 46288,
            "title": "Conflict of Interest"
        },
        {
            "endOffset": 22789,
            "parents": [],
            "secId": "sec1",
            "sentence": "Given the nature of this real-world dataset, findings are generalizable to clinical practice.",
            "startOffset": 22696,
            "title": "Introduction"
        },
        {
            "endOffset": 33174,
            "parents": [
                {
                    "id": "sec3",
                    "title": "Discussion"
                }
            ],
            "secId": "sec3.2",
            "sentence": "Furthermore, it is significant that drug level at steady state (\u22659 weeks) is also associated with response 6 months later, suggesting that there is potential to optimize therapy even once patients are established on treatment.",
            "startOffset": 32948,
            "title": "Context and clinical implications"
        },
        {
            "endOffset": 22151,
            "parents": [],
            "secId": "sec1",
            "sentence": "Here, we capitalize on a real-world bioresource from a large multicenter cohort study, Biomarkers of Systemic Treatment Outcomes in Psoriasis (BSTOP), within the UK pharmacovigilance registry British Association of Dermatologists Biologic Interventions Registry (BADBIR), to investigate the clinical utility of therapeutic drug monitoring as applied to the exemplar TNF inhibitor adalimumab.",
            "startOffset": 21760,
            "title": "Introduction"
        },
        {
            "endOffset": 44630,
            "parents": [
                {
                    "id": "sec5",
                    "title": "Materials and Methods"
                },
                {
                    "id": "sec5.5",
                    "title": "Statistical methods"
                }
            ],
            "secId": "sec5.5.2",
            "sentence": "Multivariable mixed effects logistic regression models were considered to explore the relationship between drug level and other covariates with patient response 6 months later.",
            "startOffset": 44454,
            "title": "Using drug level to predict subsequent response"
        },
        {
            "endOffset": 38457,
            "parents": [
                {
                    "id": "sec3",
                    "title": "Discussion"
                }
            ],
            "refoffsets": {
                "bib11": {
                    "endOffset": 38333,
                    "startOffset": 38312
                }
            },
            "secId": "sec3.3",
            "sentence": "Nevertheless, we identified a range comparable to that of Menting et al. (2015), who reported on trough drug levels, suggesting that limiting sampling to trough levels may not be an absolute requirement.",
            "startOffset": 38254,
            "title": "Strengths and limitations"
        },
        {
            "endOffset": 30520,
            "parents": [
                {
                    "id": "sec2",
                    "title": "Results"
                }
            ],
            "secId": "sec2.4",
            "sentence": "This has comparable diagnostic accuracy whether used to determine response on the same day as the drug level, or response 6 months later.",
            "startOffset": 30383,
            "title": "Clinical utility of the therapeutic range"
        },
        {
            "endOffset": 32567,
            "parents": [
                {
                    "id": "sec3",
                    "title": "Discussion"
                }
            ],
            "refoffsets": {
                "bib10": {
                    "endOffset": 32565,
                    "startOffset": 32547
                }
            },
            "secId": "sec3.2",
            "sentence": "This work builds on our previous pilot data showing that adalimumab levels at 4 weeks were significantly higher in responders than nonresponders (Mahil et al., 2013).",
            "startOffset": 32401,
            "title": "Context and clinical implications"
        },
        {
            "endOffset": 35509,
            "parents": [
                {
                    "id": "sec3",
                    "title": "Discussion"
                }
            ],
            "secId": "sec3.2",
            "sentence": "Our data suggest that although biologic-na\u00efve status does not appear to be important for achieving PASI75, it does appear to be influential for achieving clearance (PASI90 or PASI\u22641.5).",
            "startOffset": 35324,
            "title": "Context and clinical implications"
        },
        {
            "endOffset": 42944,
            "parents": [
                {
                    "id": "sec5",
                    "title": "Materials and Methods"
                },
                {
                    "id": "sec5.5",
                    "title": "Statistical methods"
                }
            ],
            "secId": "sec5.5.1",
            "sentence": "Multivariable mixed effects logistic regression was then used to identify an upper drug level and to explore the relationship between drug level and treatment response in the presence of other relevant covariates.",
            "startOffset": 42731,
            "title": "Identification of therapeutic range"
        },
        {
            "endOffset": 46459,
            "parents": [],
            "secId": "sec7",
            "sentence": "No other relationships or activities that could appear to have influenced the submitted work.",
            "startOffset": 46366,
            "title": "Conflict of Interest"
        },
        {
            "endOffset": 41070,
            "parents": [
                {
                    "id": "sec5",
                    "title": "Materials and Methods"
                }
            ],
            "secId": "sec5.3",
            "sentence": "In this pragmatic study, samples were not collected from every patient at every time point.",
            "startOffset": 40979,
            "title": "Pharmacokinetic measurements"
        },
        {
            "endOffset": 19994,
            "parents": [],
            "secId": "sec1",
            "sentence": "Some of this heterogeneity may be explained by differences in the amount of drug available at the target tissue, which in turn is influenced by adherence and pharmacokinetic covariates such as weight and drug immunogenicity (formation of antidrug antibodies [ADAs]).",
            "startOffset": 19728,
            "title": "Introduction"
        },
        {
            "endOffset": 28517,
            "parents": [
                {
                    "id": "sec2",
                    "title": "Results"
                },
                {
                    "id": "sec2.3",
                    "title": "Using drug level to predict subsequent response"
                }
            ],
            "secId": "sec2.3.1",
            "sentence": "Similar to the analysis using the therapeutic range dataset (exploring the relationship between drug levels and response on the same day), the probability of response at 6 months increases with increasing early drug level (PASI75: Table 3, and see Supplementary Figure S2a; PASI90 and PASI\u22641.5: see Supplementary Table S4 and Supplementary Figures S2b and c).",
            "startOffset": 28158,
            "title": "Early drug levels predict response at 6 months"
        },
        {
            "endOffset": 36173,
            "parents": [
                {
                    "id": "sec3",
                    "title": "Discussion"
                }
            ],
            "secId": "sec3.2",
            "sentence": "Finally, we have confirmed serum drug level to be the single most important factor determining treatment response, whether sampled a few weeks after treatment initiation or at steady state.",
            "startOffset": 35984,
            "title": "Context and clinical implications"
        },
        {
            "endOffset": 36331,
            "parents": [
                {
                    "id": "sec3",
                    "title": "Discussion"
                }
            ],
            "secId": "sec3.2",
            "sentence": "This underpins the importance of taking drug levels into account when searching for biomarkers and mechanisms of treatment response, such as genetic factors.",
            "startOffset": 36174,
            "title": "Context and clinical implications"
        },
        {
            "endOffset": 40978,
            "parents": [
                {
                    "id": "sec5",
                    "title": "Materials and Methods"
                }
            ],
            "secId": "sec5.3",
            "sentence": "Samples were taken without reference to treatment administration (i.e., trough/nontrough not specified) and immediately centrifuged at 2,000g for 10 minutes, and serum aliquots were frozen at \u201380 \u00b0C.",
            "startOffset": 40779,
            "title": "Pharmacokinetic measurements"
        },
        {
            "endOffset": 34209,
            "parents": [
                {
                    "id": "sec3",
                    "title": "Discussion"
                }
            ],
            "refoffsets": {
                "bib8": {
                    "endOffset": 34207,
                    "startOffset": 34184
                }
            },
            "secId": "sec3.2",
            "sentence": "This has been simulated in an RA cohort and although cost effective, it led to a reduction in quality-adjusted life years for at least a quarter of patients (Krieckaert et al., 2015).",
            "startOffset": 34026,
            "title": "Context and clinical implications"
        },
        {
            "endOffset": 21051,
            "parents": [],
            "refoffsets": {
                "bib11": {
                    "endOffset": 20992,
                    "startOffset": 20912
                },
                "bib15": {
                    "endOffset": 20992,
                    "startOffset": 20912
                },
                "bib16": {
                    "endOffset": 20992,
                    "startOffset": 20912
                },
                "bib22": {
                    "endOffset": 20992,
                    "startOffset": 20912
                }
            },
            "secId": "sec1",
            "sentence": "Effective therapeutic drug monitoring requires the definition of a therapeutic range, and although parameters for serum adalimumab levels have been proposed in the context of several IMIDs (Menting et al., 2015; Pouw et al., 2015; Roblin et al., 2014; Yarur et al., 2016), these have not yet been validated in psoriasis patients.",
            "startOffset": 20722,
            "title": "Introduction"
        },
        {
            "endOffset": 26104,
            "parents": [
                {
                    "id": "sec2",
                    "title": "Results"
                },
                {
                    "id": "sec2.2",
                    "title": "Defining the therapeutic range"
                }
            ],
            "secId": "sec2.2.2",
            "sentence": "However, the interquartile ranges on this curve show variability in response, likely caused by other clinical and confounding factors including ADAs, time from last dose, sex, age, and disease duration.",
            "startOffset": 25902,
            "title": "Likelihood of response increases with increasing drug level and then plateaus"
        },
        {
            "endOffset": 29643,
            "parents": [
                {
                    "id": "sec2",
                    "title": "Results"
                },
                {
                    "id": "sec2.3",
                    "title": "Using drug level to predict subsequent response"
                }
            ],
            "secId": "sec2.3.2",
            "sentence": "Multivariable mixed effects logistic regression modeling was carried out using the steady state dataset (drug levels taken at least 9 weeks after treatment start, with PASI recorded 6 months later) (Table 3, and see Supplementary Table S7 online).",
            "startOffset": 29396,
            "title": "Steady state drug levels predict response 6 months later"
        },
        {
            "endOffset": 21421,
            "parents": [],
            "secId": "sec1",
            "sentence": "Defining clinical outcomes in IBD and RA is inherently challenging\u2014often relying on composite indices comprising patient-reported criteria and nonspecific biochemical markers.",
            "startOffset": 21246,
            "title": "Introduction"
        },
        {
            "endOffset": 19491,
            "parents": [],
            "secId": "sec1",
            "sentence": "Complete disease remission is now achievable in people with psoriasis, rheumatoid arthritis (RA), and inflammatory bowel disease (IBD), where inhibition of the inflammatory cytokine tumor necrosis factor-\u03b1 (TNF- \u03b1) remains the first-line biologic strategy.",
            "startOffset": 19235,
            "title": "Introduction"
        },
        {
            "endOffset": 27161,
            "parents": [
                {
                    "id": "sec2",
                    "title": "Results"
                },
                {
                    "id": "sec2.2",
                    "title": "Defining the therapeutic range"
                }
            ],
            "secId": "sec2.2.3",
            "sentence": "For the PASI90 and PASI\u22641.5 outcomes, drug level remained the most important determinant of response.",
            "startOffset": 27060,
            "title": "Selecting an upper limit of the therapeutic range taking other covariates into account"
        },
        {
            "endOffset": 23751,
            "parents": [
                {
                    "id": "sec2",
                    "title": "Results"
                }
            ],
            "secId": "sec2.1",
            "sentence": "The demographics and clinical characteristics of the cohort were consistent with severe disease (predominantly male, with an elevated body mass index and mean baseline PASI of 13.5 (standard deviation = 6.7) (Table 1)).",
            "startOffset": 23532,
            "title": "Description of the cohort and patient characteristics"
        },
        {
            "endOffset": 31338,
            "parents": [
                {
                    "id": "sec3",
                    "title": "Discussion"
                }
            ],
            "secId": "sec3.1",
            "sentence": "We also show that drug levels can be used to predict response at later time points, whether taken early in the treatment course or at steady state.",
            "startOffset": 31191,
            "title": "Key results"
        },
        {
            "endOffset": 40778,
            "parents": [
                {
                    "id": "sec5",
                    "title": "Materials and Methods"
                }
            ],
            "secId": "sec5.3",
            "sentence": "Venous blood samples were collected between June 2009 and December 2016 during routine clinic reviews; samples from some BSTOP patients were taken between 2009 and 2011 as part of a pilot study with the same inclusion criteria.",
            "startOffset": 40551,
            "title": "Pharmacokinetic measurements"
        },
        {
            "endOffset": 39183,
            "parents": [],
            "secId": "sec4",
            "sentence": "These findings are of potential relevance to other IMIDs.",
            "startOffset": 39126,
            "title": "Conclusions"
        },
        {
            "endOffset": 39125,
            "parents": [],
            "secId": "sec4",
            "sentence": "Drug levels taken both early and at steady state during the treatment course could be used to predict and therefore optimize clinical outcome.",
            "startOffset": 38983,
            "title": "Conclusions"
        },
        {
            "endOffset": 24721,
            "parents": [
                {
                    "id": "sec2",
                    "title": "Results"
                },
                {
                    "id": "sec2.2",
                    "title": "Defining the therapeutic range"
                }
            ],
            "refoffsets": {
                "bib11": {
                    "endOffset": 24681,
                    "startOffset": 24661
                }
            },
            "secId": "sec2.2.1",
            "sentence": "Using the therapeutic range dataset (drug levels with PASI recorded on the same day), empirical receiver operating characteristic curves (Menting et al., 2015) were generated for all three outcomes.",
            "startOffset": 24523,
            "title": "Drug level discriminates responders from nonresponders"
        },
        {
            "endOffset": 19234,
            "parents": [],
            "secId": "sec1",
            "sentence": "Biologic therapies have transformed the treatment paradigm in immune-mediated inflammatory diseases (IMIDs).",
            "startOffset": 19126,
            "title": "Introduction"
        },
        {
            "endOffset": 37086,
            "parents": [
                {
                    "id": "sec3",
                    "title": "Discussion"
                }
            ],
            "secId": "sec3.3",
            "sentence": "To maximize inclusivity, generalizability, and sample size, we developed a prespecified research protocol with inclusion criteria designed to capture a truly representative patient sample.",
            "startOffset": 36898,
            "title": "Strengths and limitations"
        },
        {
            "endOffset": 46287,
            "parents": [],
            "secId": "sec7",
            "sentence": "NW acts as statistician on a trial funded by AstraZeneca.",
            "startOffset": 46230,
            "title": "Conflict of Interest"
        },
        {
            "endOffset": 35814,
            "parents": [
                {
                    "id": "sec3",
                    "title": "Discussion"
                }
            ],
            "secId": "sec3.2",
            "sentence": "Our findings related to ethnicity should be treated with particular caution, because very few patients within the study cohort were of non-white ethnicity.",
            "startOffset": 35659,
            "title": "Context and clinical implications"
        },
        {
            "endOffset": 27505,
            "parents": [
                {
                    "id": "sec2",
                    "title": "Results"
                },
                {
                    "id": "sec2.2",
                    "title": "Defining the therapeutic range"
                }
            ],
            "secId": "sec2.2.3",
            "sentence": "However, this should be treated with caution given the small number of patients achieving PASI90 and PASI\u22641.5 (see Supplementary Tables S3 and S4 and Supplementary Figure S1 online).",
            "startOffset": 27323,
            "title": "Selecting an upper limit of the therapeutic range taking other covariates into account"
        },
        {
            "endOffset": 40523,
            "parents": [
                {
                    "id": "sec5",
                    "title": "Materials and Methods"
                }
            ],
            "secId": "sec5.2",
            "sentence": "Clinical response is assessed longitudinally using the criterion standard assessment tool, the PASI.",
            "startOffset": 40423,
            "title": "Patients and setting"
        },
        {
            "endOffset": 41625,
            "parents": [
                {
                    "id": "sec5",
                    "title": "Materials and Methods"
                }
            ],
            "secId": "sec5.4",
            "sentence": "Primary treatment response was defined as achieving PASI75; secondary outcomes were (i) PASI90 and (ii) an absolute measure of response, PASI of 1.5 or less (see results in Supplementary Materials online).",
            "startOffset": 41420,
            "title": "Outcome measures"
        },
        {
            "endOffset": 43838,
            "parents": [
                {
                    "id": "sec5",
                    "title": "Materials and Methods"
                },
                {
                    "id": "sec5.5",
                    "title": "Statistical methods"
                }
            ],
            "refoffsets": {
                "bib13": {
                    "endOffset": 43766,
                    "startOffset": 43737
                }
            },
            "secId": "sec5.5.1",
            "sentence": "Pseudo R2 (McFadden for fixed effect models, conditional and marginal for mixed models [Nakagawa and Schielzeth, 2013]) and Akaike Information Criterion were calculated to assess model fit.",
            "startOffset": 43649,
            "title": "Identification of therapeutic range"
        },
        {
            "endOffset": 31795,
            "parents": [
                {
                    "id": "sec3",
                    "title": "Discussion"
                }
            ],
            "secId": "sec3.1",
            "sentence": "Measurement of ADA provides no additional clinical utility, presumably because of the correlation between drug levels and ADAs.",
            "startOffset": 31668,
            "title": "Key results"
        },
        {
            "endOffset": 45655,
            "parents": [],
            "secId": "sec7",
            "sentence": "JB has received honoraria, travel support, and/or research grants (King\u2019s College) from AbbVie, Pfizer, Novartis, Janssen, Roche, Regeneron, Lilly, UCB, Sun Pharma, Boehringer Ingelheim, and GSK.",
            "startOffset": 45460,
            "title": "Conflict of Interest"
        },
        {
            "endOffset": 41404,
            "parents": [
                {
                    "id": "sec5",
                    "title": "Materials and Methods"
                }
            ],
            "refoffsets": {
                "bib11": {
                    "endOffset": 41401,
                    "startOffset": 41381
                }
            },
            "secId": "sec5.3",
            "sentence": "Samples within the first year of treatment (n = 961, maximum = 4 samples/patient) were selected and sent in batches to Sanquin (Amsterdam, The Netherlands) for measurement of adalimumab concentration (ELISA, \u03bcg/ml [Menting et al., 2015]) and ADA (radioimmunoassay, ADA positive cutoff > 12 arbitrary units/ml [Menting et al., 2015]).",
            "startOffset": 41071,
            "title": "Pharmacokinetic measurements"
        },
        {
            "endOffset": 27988,
            "parents": [
                {
                    "id": "sec2",
                    "title": "Results"
                },
                {
                    "id": "sec2.3",
                    "title": "Using drug level to predict subsequent response"
                }
            ],
            "secId": "sec2.3.1",
            "sentence": "For the primary outcome of PASI75, independent predictors were (transformed) drug level and ethnicity (Table 3, and see Supplementary Table S5 online).",
            "startOffset": 27837,
            "title": "Early drug levels predict response at 6 months"
        },
        {
            "endOffset": 36897,
            "parents": [
                {
                    "id": "sec3",
                    "title": "Discussion"
                }
            ],
            "secId": "sec3.3",
            "sentence": "A key strength of this study is high external validity, because more than 50% of all UK psoriasis patients taking biologics are registered on BADBIR, and 95% of UK dermatology centers prescribing biologics for psoriasis contribute data to BADBIR.",
            "startOffset": 36651,
            "title": "Strengths and limitations"
        },
        {
            "endOffset": 43997,
            "parents": [
                {
                    "id": "sec5",
                    "title": "Materials and Methods"
                },
                {
                    "id": "sec5.5",
                    "title": "Statistical methods"
                }
            ],
            "secId": "sec5.5.1",
            "sentence": "Finally, an upper limit of the therapeutic range was defined based on this multivariable model for PASI75, with the target probability of response set at 80%.",
            "startOffset": 43839,
            "title": "Identification of therapeutic range"
        },
        {
            "endOffset": 37307,
            "parents": [
                {
                    "id": "sec3",
                    "title": "Discussion"
                }
            ],
            "secId": "sec3.3",
            "sentence": "This approach, together with the real-world nature of the cohort necessitating pragmatic sampling, introduces heterogeneity into our dataset that reflects our strategy to maximize inclusivity and minimize selection bias.",
            "startOffset": 37087,
            "title": "Strengths and limitations"
        },
        {
            "endOffset": 46229,
            "parents": [],
            "secId": "sec7",
            "sentence": "CS has received departmental research funding from AbbVie, GSK, Pfizer, Novartis, Regeneron, and Roche.",
            "startOffset": 46126,
            "title": "Conflict of Interest"
        },
        {
            "endOffset": 23427,
            "parents": [
                {
                    "id": "sec2",
                    "title": "Results"
                }
            ],
            "secId": "sec2.1",
            "sentence": "Of the 833 patients providing serum samples, 544 patients also had Psoriasis Area and Severity Index (PASI) data within 12 months of starting adalimumab (Figure 1).",
            "startOffset": 23263,
            "title": "Description of the cohort and patient characteristics"
        },
        {
            "endOffset": 25403,
            "parents": [
                {
                    "id": "sec2",
                    "title": "Results"
                },
                {
                    "id": "sec2.2",
                    "title": "Defining the therapeutic range"
                }
            ],
            "secId": "sec2.2.1",
            "sentence": "This drug level showed comparable sensitivity for the secondary outcomes of 90% improvement in baseline PASI score (PASI90) (82%) and absolute PASI of 1.5 or less (PASI\u22641.5) (85%), but specificity and overall classification accuracy were lower (see Supplementary Table S2 online).",
            "startOffset": 25123,
            "title": "Drug level discriminates responders from nonresponders"
        },
        {
            "endOffset": 37784,
            "parents": [
                {
                    "id": "sec3",
                    "title": "Discussion"
                }
            ],
            "secId": "sec3.3",
            "sentence": "Most patients in the UK receive the licensed dose for adalimumab (40 mg every 2 weeks), so although dose escalation would be a logical clinical strategy for individuals with subtherapeutic drug levels, this requires confirmation in a clinical trial setting and would have pharmacoeconomic implications.",
            "startOffset": 37482,
            "title": "Strengths and limitations"
        },
        {
            "endOffset": 39772,
            "parents": [
                {
                    "id": "sec5",
                    "title": "Materials and Methods"
                }
            ],
            "secId": "sec5.2",
            "sentence": "BSTOP is a prospective, multicenter (n = 60) observational study for establishing clinically relevant markers of outcomes to systemic therapies in people with severe psoriasis.",
            "startOffset": 39596,
            "title": "Patients and setting"
        },
        {
            "endOffset": 21563,
            "parents": [],
            "secId": "sec1",
            "sentence": "Psoriasis provides a disease model less encumbered by such issues, because treatment response can be visually observed and easily quantified.",
            "startOffset": 21422,
            "title": "Introduction"
        },
        {
            "endOffset": 29395,
            "parents": [
                {
                    "id": "sec2",
                    "title": "Results"
                },
                {
                    "id": "sec2.3",
                    "title": "Using drug level to predict subsequent response"
                }
            ],
            "secId": "sec2.3.2",
            "sentence": "Finally, we explored whether steady state drug levels in patients established on therapy could predict treatment outcomes 6 months later.",
            "startOffset": 29258,
            "title": "Steady state drug levels predict response 6 months later"
        },
        {
            "endOffset": 39967,
            "parents": [
                {
                    "id": "sec5",
                    "title": "Materials and Methods"
                }
            ],
            "secId": "sec5.2",
            "sentence": "All adults in the UK fulfilling the BSTOP inclusion criteria (BSTOP protocol available at https://bit.do/BSTOPDOCS) and enrolled onto BADBIR (http://www.badbir.org/) were invited to participate.",
            "startOffset": 39773,
            "title": "Patients and setting"
        },
        {
            "endOffset": 22695,
            "parents": [],
            "secId": "sec1",
            "sentence": "We explore the relationship between drug levels and treatment response, accounting for individual patient characteristics to determine (i) the adalimumab therapeutic range (i.e., both the minimal effective drug level and the drug level beyond which response plateaus) and (ii) whether drug level predicts longer-term response.",
            "startOffset": 22369,
            "title": "Introduction"
        },
        {
            "endOffset": 24439,
            "parents": [
                {
                    "id": "sec2",
                    "title": "Results"
                }
            ],
            "secId": "sec2.1",
            "sentence": "As Figures 1 and 2 show, three datasets were derived: a therapeutic range dataset to investigate the relationship between drug levels and same-day response, an early dataset to investigate the relationship between drug levels taken before 12 weeks and the 6-month response, and a steady state dataset to investigate the relationship between drug levels taken any time after 9 weeks and response 6 months later.",
            "startOffset": 24029,
            "title": "Description of the cohort and patient characteristics"
        },
        {
            "endOffset": 34025,
            "parents": [
                {
                    "id": "sec3",
                    "title": "Discussion"
                }
            ],
            "secId": "sec3.2",
            "sentence": "An upper limit of the therapeutic range identifies a patient population that might benefit from dose minimization.",
            "startOffset": 33911,
            "title": "Context and clinical implications"
        },
        {
            "endOffset": 43648,
            "parents": [
                {
                    "id": "sec5",
                    "title": "Materials and Methods"
                },
                {
                    "id": "sec5.5",
                    "title": "Statistical methods"
                }
            ],
            "secId": "sec5.5.1",
            "sentence": "Forward selection techniques were then used, with covariate inclusion based on significance level P < 0.05.",
            "startOffset": 43541,
            "title": "Identification of therapeutic range"
        },
        {
            "endOffset": 44847,
            "parents": [
                {
                    "id": "sec5",
                    "title": "Materials and Methods"
                },
                {
                    "id": "sec5.5",
                    "title": "Statistical methods"
                }
            ],
            "secId": "sec5.5.2",
            "sentence": "All analyses were carried out using Stata, version 14 (StataCorp, 2015) on a complete case basis.",
            "startOffset": 44750,
            "title": "Using drug level to predict subsequent response"
        },
        {
            "endOffset": 24933,
            "parents": [
                {
                    "id": "sec2",
                    "title": "Results"
                },
                {
                    "id": "sec2.2",
                    "title": "Defining the therapeutic range"
                }
            ],
            "secId": "sec2.2.1",
            "sentence": "For a 75% improvement in baseline PASI score (PASI75), drug level discriminated responders from nonresponders with an area under the curve of 0.74 (95% confidence interval [CI] = 0.68\u20130.79) (Figure 3a, Table 2).",
            "startOffset": 24722,
            "title": "Drug level discriminates responders from nonresponders"
        },
        {
            "endOffset": 32800,
            "parents": [
                {
                    "id": "sec3",
                    "title": "Discussion"
                }
            ],
            "refoffsets": {
                "bib3": {
                    "endOffset": 32712,
                    "startOffset": 32694
                }
            },
            "secId": "sec3.2",
            "sentence": "Very few studies across any IMID have paid attention to early drug levels, and to our knowledge, only one small study in IBD (Baert et al., 2014) has looked at early adalimumab levels as a predictor of subsequent treatment response.",
            "startOffset": 32568,
            "title": "Context and clinical implications"
        },
        {
            "endOffset": 42340,
            "parents": [
                {
                    "id": "sec5",
                    "title": "Materials and Methods"
                },
                {
                    "id": "sec5.5",
                    "title": "Statistical methods"
                }
            ],
            "refoffsets": {
                "bib1": {
                    "endOffset": 42294,
                    "startOffset": 42277
                }
            },
            "secId": "sec5.5.1",
            "sentence": "The therapeutic range dataset (Figures 1 and 2) included samples that were taken at steady state (\u22659 weeks [Awni et al., 2003]), with PASI scores recorded on the same day.",
            "startOffset": 42169,
            "title": "Identification of therapeutic range"
        },
        {
            "endOffset": 34958,
            "parents": [
                {
                    "id": "sec3",
                    "title": "Discussion"
                }
            ],
            "secId": "sec3.2",
            "sentence": "From a biological perspective, the finding that the clinical response rate plateaus beyond a certain drug level likely reflects the point at which most of the TNF in psoriatic skin is neutralized by adalimumab.",
            "startOffset": 34748,
            "title": "Context and clinical implications"
        }
    ],
    "docId": "S0022202X18324825",
    "metadata": {
        "asjc": [
            "1303",
            "1307",
            "1312",
            "2708"
        ],
        "authors": [
            {
                "email": null,
                "first": "Nina",
                "initial": "N.",
                "last": "Wilkinson"
            },
            {
                "email": null,
                "first": "Teresa",
                "initial": "T.",
                "last": "Tsakok"
            },
            {
                "email": null,
                "first": "Nick",
                "initial": "N.",
                "last": "Dand"
            },
            {
                "email": null,
                "first": "Karien",
                "initial": "K.",
                "last": "Bloem"
            },
            {
                "email": null,
                "first": "Michael",
                "initial": "M.",
                "last": "Duckworth"
            },
            {
                "email": null,
                "first": "David",
                "initial": "D.",
                "last": "Baudry"
            },
            {
                "email": null,
                "first": "Angela",
                "initial": "A.",
                "last": "Pushpa-Rajah"
            },
            {
                "email": null,
                "first": "Christopher E.M.",
                "initial": "C.E.M.",
                "last": "Griffiths"
            },
            {
                "email": null,
                "first": "Nick J.",
                "initial": "N.J.",
                "last": "Reynolds"
            },
            {
                "email": null,
                "first": "Jonathan",
                "initial": "J.",
                "last": "Barker"
            },
            {
                "email": null,
                "first": "Richard B.",
                "initial": "R.B.",
                "last": "Warren"
            },
            {
                "email": null,
                "first": "A. David",
                "initial": "A.D.",
                "last": "Burden"
            },
            {
                "email": null,
                "first": "Theo",
                "initial": "T.",
                "last": "Rispens"
            },
            {
                "email": null,
                "first": "Deborah",
                "initial": "D.",
                "last": "Stocken"
            },
            {
                "email": "catherine.smith@kcl.ac.uk",
                "first": "Catherine",
                "initial": "C.",
                "last": "Smith"
            },
            {
                "email": null,
                "first": null,
                "initial": null,
                "last": null
            },
            {
                "email": null,
                "first": null,
                "initial": null,
                "last": null
            }
        ],
        "doi": "10.1016/j.jid.2018.07.028",
        "firstpage": "115",
        "issn": "0022202X",
        "lastpage": "123",
        "openaccess": "Full",
        "pub_year": 2019,
        "subjareas": [
            "BIOC",
            "MEDI"
        ],
        "title": "Defining the Therapeutic Range for Adalimumab and Predicting Response in Psoriasis: A Multicenter Prospective Observational Cohort Study"
    }
}